Gomisin A enhances tumor necrosis factor-α-induced G1 cell cycle arrest via signal transducer and activator of transcription 1-mediated phosphorylation of retinoblastoma protein

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 11, 2012, Pages 1997-2003

  Waiwut, Pornthip ^a   Shin, Myoung Sook ^a   Yokoyama, Satoru ^a   Saiki, Ikuo ^a   Sakurai, Hiroaki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Cell cycle; Cyclin D1; Gomisin A; Retinoblastoma; Tumor necrosis factor

Indexed keywords

CYCLIN D1; GOMISIN A; JANUS KINASE INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; STAT1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME REPRESSION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOLECULAR MECHANICS; MONOTHERAPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CYCLOOCTANES; DIOXOLES; DRUGS, CHINESE HERBAL; G1 PHASE CELL CYCLE CHECKPOINTS; HELA CELLS; HUMANS; LIGNANS; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; SCHISANDRA; STAT1 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869235554     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00450     Document Type: Article

References (57)

1. Sun SY, Hail N Jr, Lotan R. Apoptosis as a novel target for cancer chemoprevention. J. Natl. Cancer Inst., 96, 662-672 (2004).
2. Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proc. Natl. Acad. Sci. U.S.A., 94, 2776-2778 (1997).
3. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-348 (2001).
4. Bali A, O'Brien PM, Edwards LS, Sutherland RL, Hacker NF, Henshall SM. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin. Cancer Res., 10, 5168-5177 (2004).
5. Massagué J. G1 cell-cycle control and cancer. Nature, 432, 298-306 (2004).
6. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene, 25, 5220-5227 (2006).
7. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp. Cell Res., 237, 1-6 (1997).
8. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene, 25, 1620-1628 (2006).
9. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev., 11, 957-972 (1997).
10. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J. Clin. Oncol., 23, 4215-4224 (2005).
11. Barbieri F, Lorenzi P, Ragni N, Schettini G, Bruzzo C, Pedullà F, Alama A. Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology, 66, 310-315 (2004).
12. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, Kubo T, Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene, 24, 6406-6417 (2005).
13. Zhang F, Li C, Halfter H, Liu J. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene, 22, 894-905 (2003).
14. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res., 66, 3162-3168 (2006).
15. Park S, Lee HJ, Jeong SJ, Song HS, Kim M, Lee HJ, Lee EO, Kim DH, Ahn KS, Kim SH. Inhibition of JAK1/STAT3 signaling mediates Compound K-induced apoptosis in human multiple myeloma U266 cells. Food Chem. Toxicol., 49, 1367-1372 (2011).
16. Leslie K, Lang C, Devgan G, Azare J, Berishaj M, Gerald W, Kim YB, Paz K, Darnell JE, Albanese C, Sakamaki T, Pesteil R, Bromberg J. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res., 66, 2544-2552 (2006).
17. Waiwut P, Inujima A, Inoue H, Saiki I, Sakurai H. Bufotalin sensitizes death receptor-induced apoptosis via Bid- and STAT1-dependent pathways. Int. J. Oncol., 40, 203-208 (2012).
18. Kuete V, Wabo HK, Eyong KO, Feussi MT, Wiench B, Krusche B, Tane P, Folefoc GN, Efferth T. Anticancer activities of six selected natural compounds of some Cameroonian medicinal plants. PLoS ONE, 6, e21762 (2011).
19. Li C, Yang Z, Zhai C, Qiu W, Li D, Yi Z, Wang L, Tang J, Qian M, Luo J, Liu M. Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor α by inhibiting NF-κB signaling pathway. Mol. Cancer, 9, 73 (2010).
20. Panossian A, Wikman G. Pharmacology of Schisandra chinensis BAIL.: an overview of Russian research and uses in medicine. J. Ethnopharmacol, 118, 183-212 (2008).
21. Min HY, Park EJ, Hong JY, Kang YJ, Kim SJ, Chung HJ, Woo ER, Hung TM, Youn UJ, Kim YS, Kang SS, Bae KH, Lee SK. Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells. Bioorg. Med. Chem. Lett., 18, 523-526 (2008).
22. Choi YW, Takamatsu S, Khan SI, Srinivas PV, Ferreira D, Zhao J, Khan IA. Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans. J. Nat. Prod., 69, 356-359 (2006).
23. Oh SY, Kim YH, Bae DS, Um BH, Pan CH, Kim CY, Lee HJ, Lee JK. Anti-inflammatory effects of gomisin N, gomisin J, and schisandrin C isolated from the fruit of Schisandra chinensis. Biosci. Biotechnol Biochem., 74, 285-291 (2010).
24. Li XY. Bioactivity of neolignans from fructus Schizandrae. Mem. Inst. Oswaldo Cruz, 86 (Suppl. 2), 31-37 (1991).
25. Opletal L, Sovová H, Bártlová M. Dibenzo[a,c]cyclooctadiene lignans of the genus Schisandra: importance, isolation and determination. J. Chromatogr. B, 812, 357-371 (2004).
26. Kim SH, Kim YS, Kang SS, Bae K, Hung TM, Lee SM. Antiapoptotic and hepatoprotective effects of gomisin A on fulminant hepatic failure induced by D-galactosamine and lipopolysaccharide in mice. J. Pharmacol. Sci., 106, 225-233 (2008).
27. Yasukawa K, Ikeya Y, Mitsuhashi H, Iwasaki M, Aburada M, Nakagawa S, Takeuchi M, Takido M. Gomisin A inhibits tumor promotion by 12-O- tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. Oncology, 49, 68-71 (1992).
28. Johnson CS, Chang MJ, Braunschweiger PG, Furmanski P. Acute hemorrhagic necrosis of tumors induced by interleukin-1α: effects independent of tumor necrosis factor. J. Natl Cancer Inst., 83, 842-848 (1991).
29. Kaneda Y, Yamamoto Y, Kamada H, Tsunoda S, Tsutsumi Y, Hirano T, Mayumi T. Antitumor activity of tumor necrosis factor alpha conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice. Cancer Res., 58, 290-295 (1998).
30. Roberts NJ, Zhou S, Diaz LA Jr, Holdhoff M. Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget, 2, 739-751 (2011).
31. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist, 11, 397-408 (2006).
32. Mocellin S, Pilati P, Nitti D. Towards the development of tumor necrosis factor (TNF) sensitizers: making TNF work against cancer. Curr. Pharm. Des., 13, 537-551 (2007).
33. Pilati P, Rossi CR, Mocellin S. Strategies to enhance the anticancer potential of TNF. Front. Biosci., 13, 3181-3193 (2008).
34. Waiwut P, Shin MS, Inujima A, Zhou Y, Koizumi K, Saiki I, Sakurai H. Gomisin N enhances TNF-α-induced apoptosis via inhibition of the NF-κB and EGFR survival pathways. Mol. Cell. Biochem., 350, 169-175 (2011).
35. Singhirunnusorn P, Suzuki S, Kawasaki N, Saiki I, Sakurai H. Critical roles of threonine 187 phosphorylation in cellular stress-in-duced rapid and transient activation of transforming growth factor-β-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J. Biol. Chem., 280, 7359-7368 (2005).
36. Luk SC, Siu SW, Lai CK, Wu YJ, Pang SF. Cell cycle arrest by a natural product via G2/M checkpoint. Int. J. Med. Sci., 2, 64-69 (2005).
37. Ye Y, Wang H, Chu JH, Chou GX, Chen SB, Mo H, Fong WF, Yu ZL. Atractylenolide II induces G1 cell-cycle arrest and apoptosis in B16 melanoma cells. J. Ethnopharmacol., 136, 279-282 (2011).
38. Hung DT, Jamison TF, Schreiber SL. Understanding and controlling the cell cycle with natural products. Chem. Biol., 3, 623-639 (1996).
39. Shapiro GI, Harper JW. Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest., 104, 1645-1653 (1999).
40. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif., 36, 165-175 (2003).
41. López-Guerrero JA, López-Ginés C, Pellín A, Carda C, Llombart-Bosch A. Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. Diagn. Mol. Pathol., 13, 81-91 (2004).
42. Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells chioniso patience. Cancer Res., 69, 6565-6572 (2009).
43. Du W, Searle JS. The rb pathway and cancer therapeutics. Curr. Drug Targets, 10, 581-589 (2009).
44. Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin. Cancer Res., 16, 1094-1099 (2010).
45. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer, 8, 671-682 (2008).
46. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J. Clin. Invest., 115, 2625-2632 (2005).
47. Karin M. Nuclear factor-κB in cancer development and progression. Nature, 441, 431-436 (2006).
48. Leslie K, Lang C, Devgan G, Azare J, Berishaj M, Gerald W, Kim YB, Paz K, Darnell JE, Albanese C, Sakamaki T, Pestell R, Bromberg J. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res., 66, 2544-2552 (2006).
49. Williams JG. STAT signalling in cell proliferation and in development. Curr. Opin. Genet. Dev., 10, 503-507 (2000).
50. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer, 4, 97-105 (2004).
51. Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth M, Sexl V. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell, 10, 77-87 (2006).
52. Sun L, Ma K, Wang H, Xiao F, Gao Y, Zhang W, Wang K, Gao X, Ip N, Wu Z. JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts. J. Cell Biol., 179, 129-138 (2007).
53. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer, 9, 798-809 (2009).
54. Bollrath J, Greten FR. IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep., 10, 1314-1319 (2009).
55. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R, Gabrielli B. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene, 23, 6693-6701 (2004).
56. Imanishi R, Ohtsuru A, Iwamatsu M, Iioka T, Namba H, Seto S, Yano K, Yamashita S. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J. Clin. Endocrinol. Metab., 87, 4821-4824 (2002).
57. Wang YF, Chen NS, Chung YP, Chang LH, Chiou YH, Chen CY. Sodium butyrate induces apoptosis and cell cycle arrest in primary effusion lymphoma cells independently of oxidative stress and p21 (CIP1/WAF1) induction. Mol. Cell. Biochem., 285, 51-59 (2006).